Trial Profile
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jun 2013 Planned end date changed from 1 Jun 2014 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 20 Apr 2013 Planned number of patients changed from 200 to 220 as reported by European Clinical Trials Database record.